logo

OncoTrials - мониторинг клинических исследований

Новые исследования (2025-04-02):

NCT06904599 (Реакция трансплантат против хозяина (РТПХ))


Найдено исследований: 55

NCT06636175 (добавлено: 2025-03-27)

64Cu-LLP2A for Imaging Hematologic Malignancies

Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Washington University School of Medicine; Saint Louis; Missouri; United States

NCT06622005 (добавлено: 2025-03-22)

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Roswell Park Comprehensive Cancer Center; Buffalo; New York; United States

NCT06784167 (добавлено: 2025-03-21)

Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment

Теги:  #Plasma cell leukemia 

Локации: OHSU Knight Cancer Institute; Portland; Oregon; United States

NCT06758375 (добавлено: 2025-03-21)

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Low-dose Teclistamab As Consolidation in the First-line Treatment of Patients with Newly Diagnosed Multiple Myeloma.

Теги:  #Newly diagnosed 

Локации: Hospital Universitario Dr. Jose E. Gonzalez; Monterrey; Nuevo León; Mexico

NCT06785415 (добавлено: 2025-03-20)

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Mayo Clinic in Rochester; Rochester; Minnesota; United States

NCT06028087 (добавлено: 2025-03-18)

Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment

Real-World Mapping Antithrombotic Regimens in Multiple Myeloma Patients on Treatment (The MAMMOTH Study of the GIMEMA Working Party on Hemostasis and Thrombosis)

Теги:  #Plasma cell leukemia 

Локации: Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di Ematologia; Roma; Italy

NCT06879379 (добавлено: 2025-03-18)

KPD Consolidation After ASCT in NDMM Patients

A Randomized, Multicenter Study Comparing Post-Transplant KPD Regimen Consolidation With No Consolidation in Newly Diagnosed Multiple Myeloma (NDMM) Transplant-eligible Patients

Теги:  #Newly diagnosed 

Локации: Fuxing Hospital affiliated to Capital Medical University; Beijing; Beijing; China,Peking University People`s Hospital; Beijing; Beijing; China,Shanghai Changzheng Hospital; Shanghai; Shanghai; China

NCT06880393 (добавлено: 2025-03-18)

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

A Study of BCMA CAR-T for Dynamic High-risk Patients With Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences; Tianjin; China

NCT06356571 (добавлено: 2025-03-08)

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Circuit Clinical - Buffalo - West Seneca Street- Site Number : 8400009; Buffalo; New York; United States,Michigan Hematology and Oncology Consultants- Site Number : 8400036; Dearborn; Michigan; United States,San Juan Oncology Associates- Site Number : 8400016; Farmington; New Mexico; United States

NCT06015542 (добавлено: 2025-03-06)

Self-administration of Subcutaneous Elranatamab in the Patients` Homes.

Self-administration of Subcutaneous Elranatamab in the Patients` Homes. an Open Label, Phase Two, Prospective, Non-randomized, Sponsor-initiated Explorative Trial

Теги:  #Relapsed|Refractory 

Локации: Odense University Hospital; Odense; Denmark

NCT06855121 (добавлено: 2025-03-04)

The Norwegian Immunotherapy in Multiple Myeloma Study

The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort

Теги:  #Plasma cell leukemia 

Локации: Akershus University Hospital (AHUS); Nordbyhagen; Norway,Ålesund hospital, Department of hematology; Ålesund; Norway,Bærum Hospital; Bærum; Norway,Bodø Hospital; Bodø; Norway,Diakonhjemmet hospital; Oslo; Norway,Drammen hospital; Drammen; Norway,Førde hospital; Førde; Norway,Haugesund hospital; Haugesund; Norway,Haukeland University Hospital; Bergen; Norway,Innlandet hospital trust; Gjøvik; Norway,Levanger hospital; Levanger; Norway,Lovisenberg Diaconal Hospital; Oslo; Norway,Nordmøre and Romsdal Hospital - Kristiansund; Kristiansund; Norway,Nordmøre and Romsdal Hospital - Molde; Molde; Norway,Oslo Myeloma Center, Oslo University Hospital; Oslo; Norway,Sørlandet Hospital - Arendal; Arendal; Norway,Sørlandet hospital; Kristiansand; Norway,St. Olavs hospital HF; Trondheim; Norway,Stavanger University Hospital; Stavanger; Norway,Telemark Hospital Trust; Skien; Norway,University hospital of North Norway; Tromsø; Norway,Vestfold Hospital Trust; Tønsberg; Norway,Volda hospital; Volda; Norway

NCT06846905 (добавлено: 2025-02-28)

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: CHU de Toulouse; Toulouse; France

NCT06142396 (добавлено: 2025-02-22)

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Теги:  #Newly diagnosed 

Локации: Georgia Cancer Center-Augusta University; Augusta; Georgia; United States

NCT06644625 (добавлено: 2025-02-14)

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

Теги:  #Plasma cell leukemia 

Локации: Atrium Health Levine Cancer; Charlotte; North Carolina; United States

NCT06821880 (добавлено: 2025-02-13)

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Теги:  #Plasma cell leukemia 

Локации: BKH Kufstein; Kufstein; Austria,Klinikum Garmisch-Partenkirchen; Garmisch-Partenkirchen; Germany,Medizinische Universität Graz; Graz; Austria,Medizinische Universität Innsbruck; Innsbruck; Tyrolia; Austria,Onkologischer Schwerpunkt am Oskar-Helene-Heim; Berlin; Germany

NCT06791681 (добавлено: 2025-02-12)

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

Clinical Study for Evaluating ESO-T01 Injection`s Safety and Efficacy in Treating Relapsed/refractory Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Tongji Hospital, Tongji Medical College; WuHan; Hubei; China

NCT06711705 (добавлено: 2025-02-12)

Elranatamab in Relapsed/Refractory Multiple Myeloma

Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory

Теги:  #Relapsed|Refractory 

Локации: University of California San Diego; La Jolla; California; United States

NCT06270888 (добавлено: 2025-02-07)

Hypofractionation (Radiation) Trial for Multiple Myeloma

An i3+3 Phase I Hypofractionation Trial for Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: The University of Chicago Comprehensive Cancer Center; Chicago; Illinois; United States

NCT05745285 (добавлено: 2025-02-06)

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Mays Cancer Center at UT Health San Antonio; San Antonio; Texas; United States,Sylvester Comprehensive Cancer Center; Miami; Florida; United States,University of Chicago Comprehensive Cancer Center; Chicago; Illinois; United States

NCT06668792 (добавлено: 2025-02-05)

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects with Relapsed/Refractory Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Branch of the limited liability company "Hadassah Medical LTD"; Moscow; Russian Federation,City Clinical Hospital №52 of the Department of Health of the City of Moscow; Moscow; Russian Federation,Federal State Budgetary Institution "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation; Obninsk; Russian Federation,FSBEI HE "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of Russia; Saratov; Russian Federation,FSBEI of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation; Ufa; Russian Federation,FSBEI of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation; Samara; Russian Federation,FSBI "Almazov National Medical Research Centre" of the Ministry of Health of the Russian Federation; Saint Petersburg; Russian Federation,FSBI "National Medical Research Center of Oncology named after N. N. Blokhin" of the Ministry of Health of

NCT06793449 (добавлено: 2025-01-28)

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

A Prospective, Non-inferiority Study Comparing VRD±D Followed by BCMA CAR-T Cell Therapy Versus VRD±D Followed by Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly-diagnosed Multiple Myeloma

Локации: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences; Tianjin; China

NCT06793475 (добавлено: 2025-01-28)

Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Prospective, Single-Arm, Multicenter, Open-Label Study

Теги:  #Relapsed|Refractory 

Локации: Beijing Gobroad Boren Hospital; Beijing; China,Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences; Tianjin; China

NCT06615479 (добавлено: 2025-01-28)

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Local Institution - 0001; Montreal; Quebec; Canada,Local Institution - 0003; Vancouver; British Columbia; Canada,Local Institution - 0004; Halifax; Nova Scotia; Canada,Local Institution - 0012; Nova Lima; Minas Gerais; Brazil,Local Institution - 0013; Sao Paulo; São Paulo; Brazil,Local Institution - 0016; Oslo; Norway,Local Institution - 0019; Copenhagen; Hovedstaden; Denmark,Local Institution - 0020; Aarhus; Midtjylland; Denmark,Local Institution - 0022; Odense; Syddanmark; Denmark,Local Institution - 0026; Helsinki; Uusimaa; Finland,Local Institution - 0027; Huddinge; Sweden,Local Institution - 0031; São Paulo; Brazil,Local Institution - 0044; Salt Lake City; Utah; United States,Local Institution - 0058; Atlanta; Georgia; United States,Local Institution - 0068; Madison; Wisconsin; United States,Local Institution - 0069; Calgary; Alberta; Canada,Local Institution - 0071; Birmingham; Alabama; United States,Local Institution - 0079; Creteil; Val-de-Marne; France,Local Institution - 0080; Pierre-Bénite; Rhô

NCT06669247 (добавлено: 2025-01-24)

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Illawarra Cancer Care Centre; Wollongong; New South Wales; Australia,Pindara Private Hospital; Benowa; Queensland; Australia,Royal Adelaide Hospital; Adelaide; South Australia; Australia,St Vincent`s Hospital - Melbourne; Fitzroy; Victoria; Australia

NCT06768489 (добавлено: 2025-01-11)

A Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide for Multiple Myeloma

A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide for Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Calvary Mater Newcastle Hospital; Waratah; Australia,Carmel Medical Center; Haifa; Israel,Hadassah Medical Center; Jerusalem; Israel,Hosp Clinico Univ de Salamanca; Salamanca; Spain,Hosp. Clinic de Barcelona; Barcelona; Spain,Monash Medical Centre; Clayton; Australia,Peter MacCallum Cancer Centre; Melbourne; Australia,Sheba Medical Center; Ramat Gan; Israel,St Vincents Hospital Melbourne; Fitzroy; Australia,Tel Aviv Sourasky Medical Center; Tel Aviv Yafo; Israel,UMC Utrecht; Utrecht; Netherlands,Universitair Medisch Centrum Groningen; Groningen; Netherlands,VU Medisch Centrum; Amsterdam; Netherlands

NCT06767254 (добавлено: 2025-01-10)

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: ARNAS "G. Brotzu" di Cagliari; Cagliari; Italy,Azienda Ospedaliera Universitaria Federico II; Napoli; Italy,IRCCS Azienda Ospedaliero-Universitaria di Bologna; Bologna; Italy,Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS; Meldola; Forlì-Cesena; Italy

NCT06759181 (добавлено: 2025-01-07)

Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Efficacy and Safety Study of Anti-BCMA/FcRL5 CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Xuzhou; Xuzhou; China

NCT06758713 (добавлено: 2025-01-07)

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Теги:  #Plasma cell leukemia 

Локации: The Third Affiliated Hospital of Southern Medical University; Guangzhou; Guangdong; China

NCT06679101 (добавлено: 2025-01-07)

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Теги:  #Newly diagnosed 

Локации: GSK Investigational Site; Ciudad Autonoma de Buenos Aire; Argentina,GSK Investigational Site; Hwasun; Korea, Republic of,GSK Investigational Site; Jeonju; Korea, Republic of,GSK Investigational Site; Ulsan; Korea, Republic of

NCT06691685 (добавлено: 2025-01-03)

A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan; Hubei; China

NCT06523621 (добавлено: 2024-12-28)

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Winston-Salem; North Carolina; United States,Levine Cancer Institute; Charlotte; North Carolina; United States

NCT06483100 (добавлено: 2024-12-27)

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Теги:  #Newly diagnosed 

Локации: Washington University School of Medicine; Saint Louis; Missouri; United States

NCT06645678 (добавлено: 2024-12-27)

Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma

Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/refractory Multiple Myeloma Patients

Теги:  #Relapsed|Refractory 

Локации: Seoul National University Hospital; Seoul; Korea, Republic of

NCT06604715 (добавлено: 2024-12-21)

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Clinica Univ. de Navarra; Pamplona; Spain,Hosp Univ Fund Jimenez Diaz; Madrid; Spain,Princess Margaret Hospital; Toronto; Ontario; Canada

NCT06561854 (добавлено: 2024-12-19)

Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Free Regimen of Dexamethasone as Initial Therapy for Advanced Relapsed/Refractory Multiple Myeloma: an Open-label Randomized, Non-inferiority, Controlled Trial

Теги:  #Relapsed|Refractory 

Локации: Service d`hématologie clinique et thérapie cellulaire, Saint-Antoine Hospital; Paris; France

NCT05909059 (добавлено: 2024-12-17)

CAR T-cell Therapy in Patients With Renal Dysfunction

Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction

Теги:  #Plasma cell leukemia 

Локации: Caitlin Guzowski; Atlanta; Georgia; United States

NCT06732232 (добавлено: 2024-12-14)

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: China, Shanghai Mengchao Cancer Hospital; Shanghai; China

NCT05272826 (добавлено: 2024-12-13)

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial

Теги:  #Newly diagnosed 

Локации: London Health Sciences Centre; London; Ontario; Canada,Princess Margaret Hospital; Toronto; Ontario; Canada

NCT06700395 (добавлено: 2024-12-07)

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

Phase I Clinical Study Evaluating the Tolerability and Pharmacokinetics of TQB2029 for Injection in Subjects With Multiple Myeloma

Теги:  #Plasma cell leukemia 

Локации: West China hospital, Sichuan university; Chengdu; Sichuan; China,Zhongshan Hospital of Fudan University; Shanghai; Shanghai; China

NCT06623630 (добавлено: 2024-12-06)

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Теги:  #Plasma cell leukemia 

Локации: Washington University School of Medicine; Saint Louis; Missouri; United States

NCT06718270 (добавлено: 2024-12-06)

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Shanghai Changzheng Hospital; Shanghai; Shanghai; China

NCT06477783 (добавлено: 2024-12-05)

Study on the Clinical Efficacy of Teclistamab

Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients with Relapsed and Refractory Multiple Myeloma in Belgium

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Algemeen Ziekenhuis Maria Middelares (AZMM); Gent; Oost-Vlaanderen; Belgium,AZ Delta; Roeselare; West-Vlaanderen; Belgium,AZ Groeninge; Kortrijk; West-Vlaanderen; Belgium,CHR Citadelle; Liège; Belgium,CHU Ambroise Paré; Mons; Henegouwen; Belgium,CHU Liège; Liège; Belgium,CHU UCL Namur; Yvoir; Namur; Belgium,EpiCURA; Hornu; Henegouwen; Belgium,Grand Hôpital de Charleroi; Charleroi; Henegouwen; Belgium,Imelda; Bonheiden; Antwerpen; Belgium,Institut Jules Bordet; Brussel; Vlaams-Brabant; Belgium,Jessa Ziekenhuis; Hasselt; Limburg; Belgium,UCL Saint Luc; Brussel; Vlaams-Brabant; Belgium,Universitair Ziekenhuis Antwerpen (UZA); Edegem; Antwerpen; Belgium,Universitair Ziekenhuis Gent (UZ Gent); Gent; Oost-Vlaanderen; Belgium,UZ Leuven Gasthuisberg; Leuven; Belgium,Vitaz; Sint-Niklaas; Oost-Vlaanderen; Belgium

NCT06588660 (добавлено: 2024-11-23)

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1b Study of ST-067 (Decoy-Resistant IL-18) With Teclistamab in Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Fred Hutch/University of Washington Cancer Consortium; Seattle; Washington; United States

NCT06518551 (добавлено: 2024-11-21)

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

A Phase I/II Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Beth Israel Deaconess Medical Center; Boston; Massachusetts; United States,Brigham and Women`s Hospital; Boston; Massachusetts; United States,Dana Farber Cancer Institute; Boston; Massachusetts; United States

NCT06697483 (добавлено: 2024-11-21)

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Risk Stratification and MRD-driven Maintenance for Multiple Myeloma After Autologous Stem Cell Transplantation

Теги:  #Newly diagnosed , #Plasma cell leukemia 

Локации: Fuxing Hospital; Beijing; Beijing; China,Peking Union Medical College Hospital; Beijing; Beijing; China,Peking University People`s Hospital; Beijing; Beijing; China,The First Affiliated Hospital of Harbin Medical University; Harbin; Heilongjiang; China

NCT06690593 (добавлено: 2024-11-16)

Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy

Gut Microbiota Profiling in Patients With Monoclonal Gammopathy: Implications for Disease Pathogenesis and Progression

Теги:  #Plasma cell leukemia 

Локации: Zhujiang Hospital of Southern Medical University; Guanzhou; Guangdong; China

NCT06679829 (добавлено: 2024-11-09)

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation

Теги:  #Plasma cell leukemia 

Локации: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities); Basking Ridge; New Jersey; United States,Memorial Sloan Kettering Bergen (Limited Protocol Activities); Montvale; New Jersey; United States,Memorial Sloan Kettering Cancer Center (All Protocol Activities); New York; New York; United States,Memorial Sloan Kettering Monmouth (Limited Protocol Activities); Middletown; New Jersey; United States,Memorial Sloan Kettering Nassau (Limited Protocol Activities); Uniondale; New York; United States,Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities); Commack; New York; United States,Memorial Sloan Kettering Westchester (Limited Protocol Activities); Harrison; New York; United States

NCT06630806 (добавлено: 2024-11-09)

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Investigational Site Number : 0360001; Wollongong; New South Wales; Australia,Investigational Site Number : 0360002; Melbourne; Victoria; Australia,Investigational Site Number : 1240001; Montreal; Quebec; Canada,Investigational Site Number : 1240002; Sherbrooke; Quebec; Canada,Investigational Site Number : 3760001; Tel Aviv; Israel,Investigational Site Number : 3760002; Jerusalem; Israel,Investigational Site Number : 3800001; Rozzano (MI); Italy,Investigational Site Number : 3800002; Torette; Italy

NCT06547112 (добавлено: 2024-11-05)

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Теги:  #Plasma cell leukemia 

Локации: Washington University School of Medicine; Saint Louis; Missouri; United States

NCT06171685 (добавлено: 2024-11-02)

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Atrium Levine Cancer Institute; Charlotte; North Carolina; United States,Barbara Ann Karmanos Cancer Center; Detroit; Michigan; United States,Beth Israel Deaconess Medical Center; Boston; Massachusetts; United States,City of Hope; Duarte; California; United States,Dana Farber Cancer Institute/Harvard Medical School; Boston; Massachusetts; United States,Emory Winship Cancer Center; Atlanta; Georgia; United States,Hackensack University Medical Center; Hackensack; New Jersey; United States,Mayo Clinic Rochester; Rochester; Minnesota; United States,Memorial Sloan Kettering Cancer Center; New York; New York; United States,Mt. Sinai School of Medicine; New York; New York; United States,Tennessee Oncology; Nashville; Tennessee; United States,University of Chicago Cancer Center; Chicago; Illinois; United States,Washington University Medicine; Saint Louis; Missouri; United States,Washington University Medicine; St. Louis; Missouri; United States

NCT06663046 (добавлено: 2024-11-02)

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

A Clinical Study Evaluating the Safety and Efficacy of Universal BCMA-Targeted CAR-T (UWD-00B) Therapy for Refractory and Relapsed Multiple Myeloma

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: The First Affiliated Hospital of University of Science and Technology of China Hefei,; Hefei; Anhui; China

NCT06465316 (добавлено: 2024-10-23)

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma

Теги:  #Relapsed|Refractory 

Локации: Dana-Farber - Harvard Cancer Center LAO; Boston; Massachusetts; United States,Moffitt Cancer Center; Tampa; Florida; United States,Ohio State University Comprehensive Cancer Center; Columbus; Ohio; United States,University of Oklahoma Health Sciences Center; Oklahoma City; Oklahoma; United States,Virginia Commonwealth University/Massey Cancer Center; Richmond; Virginia; United States

NCT06644118 (добавлено: 2024-10-17)

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Pilot Clinical Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Теги:  #Relapsed|Refractory 

Локации: Beijing Gobroad Boren Hospital; Beijing; Beijing; China,The Affiliated Hospital of Northwest University Xi`an No.3 Hospital; Xi`an; Shanxi; China,The First Affiliated Hospital, College of Medicine, Zhejiang University; Hangzhou; Zhejiang; China

NCT06559709 (добавлено: 2024-10-15)

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Implementing a Plant-Based Whole-Foods Meal Delivery Service for Patients Undergoing Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: A Pilot Study

Теги:  #Plasma cell leukemia 

Локации: Fred Hutch/University of Washington Cancer Consortium; Seattle; Washington; United States

NCT06245629 (добавлено: 2024-10-15)

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study

Теги:  #Plasma cell leukemia , #Relapsed|Refractory 

Локации: Akademiska sjukhuset; Uppsala; Sweden